Showing results (521-530 of 652) with videos related to

Sort By:
Pageof 66
Lancet (London, England)|September 7, 2015
Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trialReena Khanna, Brian Bressler, Barrett G Levesque, et al.
Journal of Crohn'S & Colitis|October 5, 2023
Maintenance Risankizumab Sustains Induction Response in Patients with Crohn's Disease in a Randomized Phase 3 TrialMarc Ferrante, Peter M Irving, Maria T Abreu, et al.
Ebiomedicine|July 3, 2017
The NOD2-Smoking Interaction in Crohn's Disease is likely Specific to the 1007fs Mutation and may be Explained by Age at Diagnosis: A Meta-Analysis and Case-Only StudyM Ellen Kuenzig, Jeff Yim, Stephanie Coward, et al.
Journal of Crohn'S & Colitis|November 9, 2025
Placebo rates in randomized clinical trials of ulcerative colitis: an individual patient data meta-analysisVirginia Solitano, Malcolm Hogan, Siddharth Singh, et al.
Gut|December 11, 2025
Preclinical stages of Crohn's disease defined by faecal calprotectin in asymptomatic first-degree relatives: screening framework for prevention trialsDan Turner, Sarah Kenigsberg, Gili Focht, et al.
Physical Review Letters|July 29, 2017
Three-Dimensional Electronic Structure of the Type-II Weyl Semimetal WTe_{2}Domenico Di Sante, Pranab Kumar Das, C Bigi, et al.
Journal of Crohn'S & Colitis|September 30, 2016
Long-term Efficacy of Vedolizumab for Crohn's DiseaseSeverine Vermeire, Edward V Loftus, Jean-Frédéric Colombel, et al.
Inflammatory Bowel Diseases|March 27, 2024
Crohn's Disease Phenotypes and Associations With Comorbidities, Surgery Risk, Medications and Nonmedication Approaches: The MAGIC in IMAGINE StudyCharles N Bernstein, Remo Panaccione, Zoann Nugent, et al.
The American Journal of Gastroenterology|January 11, 2017
Responsiveness of Endoscopic Indices of Disease Activity for Crohn's DiseaseReena Khanna, GuangYong Zou, Larry Stitt, et al.
Alimentary Pharmacology & Therapeutics|March 3, 2017
Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn's disease: real world experience from a multicentre cohortC Ma, R N Fedorak, G G Kaplan, et al.
Pageof 66